Business
‘Groundbreaking approach’: Imugene deal looks to smash solid tumours – Sydney Morning Herald
The $1.5 billion biotech will work with Nasdaq-listed firm Celularity in hopes of cracking the mystery of how to target tough…
Imugene, the cancer treatment maker chaired by biotech veteran Paul Hopper, is banking on a partnership with Nasdaq-listed biotech Celularity to unlock a revolutionary treatment that will obliterate solid tumours.
The Sydney-based company, which has seen…
-
Noosa News17 hours agoPhotographer Nadia Shevtsova remembered by family in touching tribute after deadly crash at Gold Coast
-
General12 hours agoMajority of Australia’s first Ashes Test squad to feature in Sheffield Shield round four
-
Noosa News20 hours agoWoman’s lucky escape after car rolls and crashes onto tracks before being hit by oncoming train in Kingston, Logan
-
General8 hours agoFrom jackaroo to ‘Golden Tonsils’ radio titan: the life and career of John Laws